We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Teva Settles Nexium Pay-for-Delay Suit for $24 Million

Teva Settles Nexium Pay-for-Delay Suit for $24 Million

June 19, 2015

Israeli drugmaker Teva will pay $24 million to settle a pay-for-delay lawsuit over its generic version of AstraZeneca’s heartburn relief drug Nexium.

Massachusetts federal Judge William G. Young approved the settlement, which resulted from an agreement drafted in April. Teva made no admission regarding the claims against it, and plaintiffs’ claims were dismissed.

The lawsuit does not include drugmakers AstraZeneca, Ranbaxy or Dr. Reddy’s Laboratories, which are alleged to have participated in the scheme to delay generic versions of Nexium getting to market. Dr. Reddy’s previously settled a similar lawsuit.

In December, a jury found that AZ and Ranbaxy, the two remaining defendants in the lawsuit, did not conspire to delay launching a generic version of Nexium when they signed a “no authorized generics” pledge in a 2008 settlement agreement. Earlier this month, plaintiffs sought an injunction against AZ and Ranbaxy as they seek a retrial.

Industry has paid close attention to the lawsuit In Re: Nexium (esomeprazole) Antitrust Litigation because it tests what kinds of patent infringement settlements are permissible following the Supreme Court’s 2013 ruling in the FTC v. Actavis antitrust case.

The plaintiffs had claimed AZ’s settlements amounted to cash transactions. AZ, however, contended that its deal with Teva involved waiving part of a debt that the generics maker owed the brand maker for a separate patent lawsuit and not a direct payment.

Under terms of Teva’s settlement, the plaintiffs are divided into direct purchaser, individual retailer and end-payer groups. The end-payer group will get $1 million, from which $5,000 incentive awards will be paid to each plaintiff. The other two groups will split the remaining funds minus fees and expenses, with 61 percent earmarked for direct purchasers and 39 percent for individual retailers.

In January, the FDA approved Teva’s plan to market a generic Nexium (delayed-release esomeprazole magnesium), snubbing Ranbaxy’s ANDA first-filer status over GMP violations at a plant in India.

Teva offered no comment on the settlement. — John Bechtel

Pharmaceuticals Submissions and Approvals Commercial Operations

Upcoming Events

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 27Jul

    Applying the Lessons of the Pandemic to Your Upcoming Trial

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Warns Baby Neck Floats Used in Water Therapy Can Cause Death or Injury

  • U.S. Government Inks $3.2 Billion Contract With Pfizer-BioNTech for Vaccine Booster Campaign

  • FX Receives FDA Clearance for Its FX V135 Shoulder Arthroplasty Platform

  • FDA Recommends Modified COVID-19 Vaccine Boosters Adapted to Omicron BA.4 and BA.5 Subvariants

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing